Search Within

Alison Moskowitz

  1. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (123)
  2. Journal Article (83)
  3. Research Letter (7)
  4. Review (5)
  5. Correspondence (1)
  6. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (220)
  2. Department of Medicine (220)
  3. Hematologic Malignancies, Division of (220)
  4. Lymphoma (220)
  5. Population Sciences Research Program (220)
  6. Survivorship Research (114)

More Groups

People
  1. Steven Horwitz (220)
  2. Andrew Zelenetz (102)
  3. Ariela Noy (99)
  4. Paul Hamlin (95)
  5. Maria Palomba (90)
  6. David Straus (89)

More People

Years
  1. 2025 (5)
  2. 2024 (14)
  3. 2023 (21)
  4. 2022 (13)
  5. 2021 (24)
  6. 2020 (24)

More Years

Publications
  1. Blood (92)
  2. Hematological Oncology (15)
  3. Journal of Clinical Oncology (15)
  4. Journal of the American Academy of Dermatology (12)
  5. Blood Advances (10)
  6. Blood Cancer Journal (8)

More Publications

Publishers
  1. American Society of Hematology (102)
  2. Wiley Blackwell (21)
  3. American Society of Clinical Oncology (15)
  4. Elsevier Inc. (12)
  5. Mosby Elsevier (12)
  6. Nature Publishing Group (11)

More Publishers

Results (220)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas
    Meeting Abstract

    Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
    Journal Article

    Bobillo, S.; Joffe, E.; Sermer, D.; Mondello, P.; Ghione, P.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; more...
    Blood Cancer Journal (2021)

    Fulltext@MSK | Save
  • Quality of life effect of the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in patients with cutaneous T-cell lymphoma
    Journal Article

    Porcu, P.; Hudgens, S.; Horwitz, S.; Quaglino, P.; Cowan, R.; Geskin, L.; Beylot-Barry, M.; Floden, L.; Bagot, M.; Tsianakas, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
    Journal Article

    Joffe, E.; Leyfman, Y.; Drill, E.; Rajeeve, S.; Zelenetz, A. D.; Lia Palomba, M.; Moskowitz, C. H.; Portlock, C.; Noy, A.; Horwitz, S. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
    Journal Article

    Bobillo, S.; Joffe, E.; Lavery, J. A.; Sermer, D.; Ghione, P.; Noy, A.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma (PTCL)
    Meeting Abstract

    Ruan, J.; Moskowitz, A. J.; Mehta-Shah, N.; Sokol, L.; Chen, Z.; Rahim, R.; Song, W.; Van Besien, K.; Horwitz, S. M.; Rutherford, S. C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Favorable outcomes among patients with T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era
    Meeting Abstract

    Robin, E. T.; Drill, E.; Batlevi, C. L.; Caron, P.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Joffe, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save